Chief Accounting Officer
CytomX Therapeutics, Inc. (CTMX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Chris Ogden is recorded as CFO and Chief Accounting Officer at CytomX Therapeutics, Inc. (CTMX). CytomX Therapeutics, Inc. reported in an 8-K filed June 17, 2024 that Chris Ogden was appointed Chief Financial Officer, effective June 15, 2024. CytomX Therapeutics, Inc. reported in an 8-K filed September 23, 2022 that Chris Ogden was appointed principal financial officer and principal accounting officer, effective September 21, 2022. Chris Ogden has spoken on 14 earnings calls and 1 other investor event across 1 company, most recently for CytomX Therapeutics, Inc. on September 14, 2026.
“On June 12, 2024, CytomX Therapeutics, Inc. (the "Company") appointed Chris Ogden to serve as the Company's Chief Financial Officer effective June 15, 2024 (the "Effective Date").”
“On September 21, 2022, the Board of Directors (the "Board") of CytomX Therapeutics, Inc. (the "Company") designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately, in connection to the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2022-02-14–present
Start not stated–present
Proxy statement
Start not stated–2022-04-27
Last confirmed by a filing; no departure on record
Recorded roles and call appearances connecting this person to public companies.
CFO, Chief Accounting Officer
2022-02-14–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
